Chronic Lymphocytic Leukemia | Specialty

Emerging Agents Signal Promising Opportunities to Expand Treatment Options for CLL

December 15th 2022

Anthony Mato, MD, MSCE, discusses the relapsed refractory setting compared with the frontline setting and promising agents such as pirtobrutinib and zanubrutinib.

BGB-11417 Alone or in Combination with Zanubrutinib Shows Early Efficacy in CLL/SLL

December 13th 2022

BGB-11417, when given alone or in combination with zanubrutinib, elicited encouraging responses and minimal residual disease negativity rates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to preliminary data from a phase 1 trial.

Unveiling Practice-Changing Data in CLL, GVHD, and MPNs: Drs Catherine Coombs, Nelli Bejanyan, and Aaron Gerds

December 13th 2022

Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL

December 13th 2022

Treatment with zanubrutinib (Brukinsa) reduced the risk of progression or death by 35% compared with ibrutinib (Imbruvica) for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Zilovertamab/Ibrutinib Elicits Durable Responses With Favorable Tolerability in MCL and CLL

December 11th 2022

The combination of zilovertamab and ibrutinib resulted in promising clinical response and progression-free survival rates and showcased a tolerable toxicity profile in patients with mantle cell lymphoma and chronic lymphocytic leukemia.

Dr. Rhodes on Evaluating the Unmet Needs of Elderly Patients in CLL

December 2nd 2022

Joanna M. Rhodes, MD, discusses evaluating the unmet needs of elderly patients in CLL.

European Commission Approves Zanubrutinib for CLL

November 18th 2022

The European Commission has approved zanubrutinib for the treatment of adult patients with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia.

Closing Remarks on Unmet Needs in R/R FL

November 10th 2022

Dr Hill closes by discussing current unmet needs in the R/R FL landscape and giving practical advice to providers caring for patients with FL.

CAR T-cell Options for Patients with R/R FL

November 10th 2022

A focused discussion on available CAR T-cell therapies for patients with R/R FL, supporting efficacy data, and how these therapies have impacted the field.

Addressing Intolerance and Resistance to BTK Inhibition Is Next Frontier in CLL Drug Development

November 9th 2022

The development of agents to address intolerance and acquired resistance to BTK inhibitors addresses 2 of the major unmet needs for patients with chronic lymphocytic leukemia.

Dr. Awan on Selecting BTK Inhibitors for CLL Management

November 7th 2022

Farrukh Awan, MD, discusses the current use of BTK inhibitors in the management of chronic lymphocytic leukemia and important factors to consider when determining the best treatment strategy.

Ibrutinib Demonstrates Long-Term Efficacy in CLL in Real-World Setting

November 3rd 2022

Ibrutinib induced a cumulative overall response rate of 90.0% in 3-year findings from the Belgian Ibrutinib Real‑World Data study of patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia.

Considerations for Treatment Selection in the Third-Line R/R FL Setting

November 3rd 2022

Dr Hill shares how he would have handled the patient case and discusses factors that contribute to treatment selection among third-line therapies for patients with R/R FL, including axicabtagene ciloleucel and other CAR T-cell therapies.

Typical Treatment Responses in Patients with FL and Incidence of Relapsed or Refractory Disease

November 3rd 2022

Insights concerning typical treatment responses experienced by patients with FL, clinical factors that may be predictive of response, and the incidence of relapsed or refractory disease.

First Patient Dosed With Menin Inhibitor BMF-219 in COVALENT-101 Trial in CLL

November 1st 2022

The first patient in the chronic lymphocytic leukemia cohort has been dosed in the phase 1 COVALENT-101 trial, which is evaluating the first-in-class covalent menin inhibitor BMF-219.

First-, Second-, and Third-Line Treatment Selection for a FL Patient Case

October 27th 2022

Dr Hill continues his discussion of the case, outlining the first-, second, and third-line treatment strategies employed for this particular patient.

Follicular Lymphoma Background and Introduction to a Patient Case

October 27th 2022

Brian T. Hill, MD, PhD briefly reviews the diagnosis and staging of FL, typical prognoses for patients with the disease, and begins to outline a patient case of R/R FL.

Novel Therapies Provide a Wealth of Individualized Treatment Options in CLL and MCL

October 20th 2022

Farrukh Awan, MD, discusses new agents under investigation in chronic lymphocytic leukemia and mantle cell lymphoma and emphasizes the importance of weighing each drug’s risks and benefits against individual patient needs and preferences to make informed decisions.

Dr. Awan on the Evolution of Treating Frontline CLL

October 18th 2022

Farrukh Awan, MD, discusses the evolution of treating frontline chronic lymphocytic leukemia.

Dr. Ryan on the Efficacy of Ibrutinib Plus Obinutuzumab in Relapsed/Refractory CLL

October 14th 2022

Christine Ryan, MD, discusses the significance of data for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.